Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Authored Items
Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma.
Read More ›
Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC.
Read More ›
Key Abstracts from ASCO 2021 in NSCLC
By
Mark A. Socinski, MD
American Society of Clinical Oncology (ASCO)
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of
EGFR
inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.
Read More ›
Practice-Changing Data in NSCLC from ASCO 2021
By
Mark A. Socinski, MD
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski provides his insights into important new data on
EGFR
inhibitors and immunotherapy in the first-line setting for NSCLC.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us